Actively Recruiting
Creation of a Biocollection of Patients With Acute Myeloid Leukemia (AML), Acute Lymphoid Leukemia (ALL), or High-risk Myelodysplastic Syndrome (MDS) Monitored at Nantes University Hospital
Led by Nantes University Hospital · Updated on 2026-05-29
1000
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are collecting blood and bone marrow samples from patients with Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL), or high-risk myelodysplastic syndrome (MDS) at Nantes University Hospital to support research. The goal is to analyze these samples to better understand these diseases and identify new biomarkers or therapeutic targets. This study is observational and aims to improve knowledge of tumor characteristics and their microenvironment in these conditions. Patients included in the study will provide additional blood or bone marrow samples only when these are already planned as part of their routine care. Samples may be collected at diagnosis or relapse and, depending on research needs, up to one additional sample each month for three months after inclusion. Collected samples will be sent to research laboratories immediately or stored for future analysis under the care of the clinical hematology department. Participants will be monitored through sample collections linked to their treatment schedule. Researchers will study genetic factors and plasma cytokine levels using advanced techniques like transcriptome analysis and flow cytometry. The main outcome is to characterize tumors and their environments to find new treatment targets, with results reviewed one year after inclusion. Participation involves no extra punctures beyond clinical care, and samples may be collected up to four times within three months after joining the biocollection.
CONDITIONS
Brief Title
Creation of a Biocollection of Patients With Acute Myeloid Leukemia (AML) or Lymphoid Leukemia (ALL) or High-risk Myelodysplastic Syndrome (MDS) Monitored at the Nantes University Hospital
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patient is 18 years or older
- Diagnosed with AML, ALL, or high-risk MDS regardless of treatment stage
- Signed informed consent form
- Affiliated with a social security system
You will not qualify if you...
- Minor patients
- Adults under legal guardianship
- Protected persons unable to consent for themselves
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - At inclusion
Blood and bone marrow samples are collected at the time of diagnosis or relapse for biological analysis.
1 visit (in-person)
Duration - Up to 3 months after inclusion
Participants who undergo routine care are observed. Additional blood and bone marrow samples may be collected up to once a month for three months following inclusion depending on ongoing biological study needs.
Up to 4 visits (in-person)
Trial Site Locations
Total: 1 location
1
Nantes University Hospital
Nantes, France
Actively Recruiting
Research Team
P
Pierre Perterlin
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here